← Back to newsBODYPORT / NEWS & RESEARCH

November 9, 2025

AHA presentation demonstrating the complementary value of the Bodyport Congestion Index and PA pressure monitoring in heart failure patients

In this demonstration, we show the complementary value of the Bodyport Congestion Index and PA pressure monitoring in heart failure patients. Read more here.

‍

← All news and announcements Clinical evidence →

About Bodyport

Bodyport develops remote monitoring technologies for patients with fluid management-related health conditions. The FDA-cleared Bodyport Cardiac Scale measures weight, peripheral impedance, pulse rate, and balance through a simple daily measurement. Bodyport’s clinician-facing software combines longitudinal data into the Congestion Index, a clinical decision support tool that helps healthcare professionals identify and evaluate changes associated with worsening congestion. Based in San Francisco, the company is backed by top-tier investors including Boehringer Ingelheim Venture Fund, Terumo Medical, Initialized Capital, Playground Global, Rock Health, and Y Combinator. For more information, visit bodyport.com and follow the company on LinkedIn and Twitter.